A study showing that one in four insulin-treated patients surveyed at an urban US diabetes center were found to be cutting back on insulin use because of cost has been published.
The survey results also reveal that cost-related insulin underuse was associated with worse glycemic control and that more than a third of patients did not discuss the insulin underuse with their clinicians.
Of those who completed the survey, 25.5% (51) reported cost-related insulin underuse.
[inlinetweet prefix=”” tweeter=”” suffix=””]U.S. adults, internet use for health information is vast and growing; 8 in 10 adults say they use the internet for health and wellness purposes, an increase of 13% since 2015. (Source: Kantar)[/inlinetweet]
T[inlinetweet prefix=”” tweeter=”” suffix=””]two in five ailment sufferers have seen or heard healthcare advertising on the internet or on a mobile device within the last year. (Kantar)[/inlinetweet]
Among the 61% of patients who had researched prescription drugs online in the past 12 months, 34% had requested a specific prescription drug at least once.
Among patients who had requested an Rx, 25% were prompted to do so by a TV ad and 25% by ads seen online. (DRG)
[inlinetweet prefix=”” tweeter=”” suffix=””]An average 80 DTC ads air every hour on TV[/inlinetweet] (Axios)
Oncology DTC ads promise a lot, but the therapies are not right for everyone.
Many of these treatments bring risks of painful — even life-threatening— side effects and carry total price tags pushing $1 million.
There are few objective guideposts to determine which patients should get which treatments, or even undergo genetic testing to determine whether they are among the minority of patients who might benefit substantially from immuno-oncology medicines. (Source:STAT News)